Cycloimidamicins, Novel natural lead compounds for translation inhibition in Pseudomonas aeruginosa.
Yoshimasa IshizakiMaya UmekitaRie ArisakaMasaki HatanoTomoyuki KimuraYumiko KubotaYuko ShibuyaChigusa HayashiRyuichi SawaMasayuki IgarashiPublished in: The Journal of antibiotics (2023)
Pseudomonas aeruginosa is one of the most concerning pathogenic bacteria. We screened antibiotics using a highly drug-sensitive P. aeruginosa strain and an oligotrophic medium, and successfully isolated novel antibiotics, namely cycloimidamicins (CIMs), from a rare actinomycete strain, Lentzea sp. MM249-143F7. X-ray and nuclear magnetic resonance analyses revealed that CIMs possess a distinctive and unprecedented molecular structure, containing tetramic acid and an imidazole ring bound directly to indolone. The CIMs exhibited potent antibacterial activity against Gram-negative bacteria, as well as translation inhibition in Escherichia coli in both intact cells and in vitro. Additionally, E. coli strains resistant to known translation inhibitors did not exhibit cross-resistance to CIMs, suggesting that CIMs inhibit bacterial growth by blocking translation through a novel mechanism.
Keyphrases
- escherichia coli
- pseudomonas aeruginosa
- magnetic resonance
- biofilm formation
- cystic fibrosis
- induced apoptosis
- high resolution
- acinetobacter baumannii
- cell cycle arrest
- computed tomography
- single cell
- cell death
- signaling pathway
- dual energy
- single molecule
- cell proliferation
- candida albicans
- electronic health record